医学全在线
医学全在线首页-医师-药师-护士-卫生资格-高级职称-考试题库-网校-考研-图谱-下载-招聘-论坛  
分类
国家级省级浙江省各省杂志
科技核心北大核心CSCDCSCD扩展
工具
期刊知识写作指导 论文投稿推荐期刊
期刊验证论文检测 录用通知往期目录
SCI
SCI指导影响因子
期刊点评基金动态
其它
经济教育计算机
建筑体育农业
北京|天津|河北|山西|湖北|江苏|安徽|山东|上海|浙江|江西|福建|湖南|宁夏|内蒙古|河南
四川|重庆|贵州|云南|辽宁|吉林|广东|广西|海南|陕西|甘肃|新疆|青海|卫生部直属|黑龙江|兵团
您现在的位置: 医学全在线 > 医学论文 > 论文投稿 > 正文:不同剂量阿托伐他汀对肺心病患者bigET及hsCRP及PAP水平的影响
    

医学论文范文:不同剂量阿托伐他汀对肺心病患者bigET及hsCRP及PAP水平的影响

来源:本站原创 更新:2013-9-5 论文投稿平台

医学论文范文:不同剂量阿托伐他汀对肺心病患者bigET及hsCRP及PAP水平的影响

【摘要】 目的 对肺心病并高脂血症患者应用不同剂量阿托伐他汀治疗,观察其调脂的同时对大内皮素(bigET)及超敏C反应蛋白(hsCRP)的影响,及肺动脉压力(PAP)改变情况。方法 将在我院就诊的肺心病高脂血症患者100例,随机分为2组,即A组(阿托伐他汀10 mg,每晚1次)、B组(阿托伐他汀20 mg,每晚1次)。2组之间匹配非处理因素,比较2组治疗24周后血脂水平,bigET及HsCRP、PAP变化情况。结果 2组在治疗24周后血脂及内皮功能、肺动脉压力均有改善,血清hsCRP水平均有降低(P<0.05), B组24周后bigET水平及hsCRP水平明显低于A组(P<0.05)。PAP改善B组较A组明显(P<0.05)。2组之间不良反应率间差异有统计学意义(P<0.01)。结论 他汀类药物在调脂的同时具有非调脂依赖性心脏保护作用,可改善血管内皮功能、抑制慢性炎症反应,降低肺动脉压力、改善心功能,并随剂量的增加其作用增加。

【关键词】 肺心病;高脂血症;内皮缩血管肽类;超敏C反应蛋白;阿托伐他汀

Effects of different doses of atorvastatin on serum lipids, bigET, hsCRP and PAP in hyperlipidemia patients with chronic cor pulmonale ZHU Yanhui, WANG Xizhu, SONG Qiaofeng, et al.Department of Cardiology, People’s Hospital of Tangshan city,Hebei,Tangshan 063000,China

【Abstract】 Objective To investigate the safety and therapeutic effect of different doses of atorvastatin on lipidlowering,endothelial function,highsensitivity Creactive protein(hsCRP)and pulmonary artery pressure(PAP)in hyperlipidemia patients with chronic cor pulmonale.Methods 100 hyperlipidemia patients with chronic cor pulmonale were randomly divided into two groups.The patients in disorder lipidemia group were given atorvastatin 10mg qd or 20 mg qd for 24 weeks. The levels of TC, TG, LDLC, HDLC, bigET and hsCRP, PAP were determined in disorder lipidemia groups 24 hours after pretreatment or treatment.Results TC and LDLC were decreased significantly(P<0.05)in both groups after 24 weeks, but the decrease in atorvastatin 20mg qd group was more obvious. BigET in atorvastatin 20mg qd group was reduced from (0.69±0.26 )pmol/L before treatment to (0.43±0.07) pmol/L after 24week treatment,which also was significantly lower than that of atorvastatin 10mg qd group(0.51±0.08)pmol/L (P<0.05). hsCRP in atorvastatin 20mg qd group was decreased from(7.1±2.1)mg/L before treatment to(3.8±0.4)mg/L after 24week treatment, which was significantly lower than that of atorvastatin 10mg qd group(4.4±0.6) mg/L(P<0.05). PAP in atorvastatin 20mg qd group was reduced from(54±18)mmHg before treatment to(30±7)mmHg after 24week treatment, which was significantly lower than that of atorvastatin 10mg qd group(42±8)mmHg(P<0.05).Conclusion The atorvanstain can reduce obviously blood lipid,hsCRP and PAP,and can improve endothelial function. The administration of atorvanstain 20mg qd is safe, which is effective in controlling blood lipid,decreasing hsCRP,PAP and improving endothelial function医.学全.在.线网站www.med126.com.

【Key words】 pulmonary heart disease; hyperlipidemia; endothelins;highsensitivity Creactive protein;atorvastatin


[1] [2] [3] [4] [5] 下一页

...
关于我们 - 联系我们 -版权申明 -诚聘英才 - 网站地图 - 医学论坛 - 医学博客 - 网络课程 - 帮助
医学全在线 版权所有© CopyRight 2006-2046, MED126.COM, All Rights Reserved
浙ICP备12017320号
百度大联盟认证绿色会员实名网站 360认证可信网站 中网验证